2-Methoxy-5-(5-methyl-1,3-benzoxazol-2-yl)aniline | 312603-83-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Methoxy-5-(5-methyl-1,3-benzoxazol-2-yl)aniline
• CAS: 312603-83-1
• 化学式: C₁₅H₁₄N₂O₂
• mdl: MFCD00579073
• 分子量: 254.288
• InChiKey: KZEVRQKQRHFTCW-UHFFFAOYSA-N

物化性质

• 沸点：
  411.5±40.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  偏苯三酸酐 、 2-Methoxy-5-(5-methyl-1,3-benzoxazol-2-yl)aniline 在 溶剂黄146 作用下， 生成 2-[2-Methoxy-5-(5-methyl-benzooxazol-2-yl)-phenyl]-1,3-dioxo-indan-5-carboxylic acid
  参考文献：
  名称：

  2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

  摘要：

  A novel class of 2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids are described as inhibitors of the endo-beta-glucuronidase heparanase. Several of the compounds, for example, 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-yl]phenyl]-2,3-dihydro-1,3-dioxo-IH-isoindole-5-carboxylic acid (9c), display potent heparanase inhibitory activity (IC50 200-500nM) and have high selectivity ( > 100-fold) over human beta-glucuronidase. They also show anti-angiogenic effects. Such compounds should serve as useful biological tools and may provide a basis for the design of novel therapeutic agents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.086
• 作为产物：
  描述：

  4-甲氧基-3-硝基苯甲酸 在 palladium on activated charcoal 草酰氯 、 氢气 、 对甲苯磺酸 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙酸乙酯 、 甲苯 为溶剂， 生成 2-Methoxy-5-(5-methyl-1,3-benzoxazol-2-yl)aniline
  参考文献：
  名称：

  2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

  摘要：

  A novel class of 2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids are described as inhibitors of the endo-beta-glucuronidase heparanase. Several of the compounds, for example, 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-yl]phenyl]-2,3-dihydro-1,3-dioxo-IH-isoindole-5-carboxylic acid (9c), display potent heparanase inhibitory activity (IC50 200-500nM) and have high selectivity ( > 100-fold) over human beta-glucuronidase. They also show anti-angiogenic effects. Such compounds should serve as useful biological tools and may provide a basis for the design of novel therapeutic agents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.086

文献信息

• BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE
  申请人：Jensen Roy A.

  公开号：US20090170842A1

  公开（公告）日：2009-07-02

  A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.

  一种用于治疗、抑制和/或预防乳腺和/或卵巢癌的药物组合物可以包括：具有化合物1-38中一种的结构，其药学上可接受的盐或类似物，以及含有该化合物的药学上可接受的载体。药学上可接受的载体可以配置为口服、全身性、经皮、鼻内、栓剂、静脉注射、肌肉注射或皮下注射的给药途径。该化合物可以以治疗、抑制和/或预防乳腺和/或卵巢癌的治疗有效量存在于组合物中。此外，该化合物可以以增强BRCA1产生的治疗有效量存在于组合物中。
• BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use
  申请人：Jensen Roy A.

  公开号：US20120259005A1

  公开（公告）日：2012-10-11

  A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.
• US8362072B2
  申请人：——

  公开号：US8362072B2

  公开（公告）日：2013-01-29